INTRODUCTION

Intracranial germ cell tumors (GCTs) are a group of rare and heterogeneous with very little is known about their pathogenesis and underlying genetic abnormalities. Procedures. In order to identify candidate genes and pathways which are involved in the pathogenesis of these tumors, we have profiled 62 intracranial GCTs for DNA copy number alterations (CNAs) and loss of heterozygosity (LOH) by using single nucleotide polymorphism (SNP) array and quantitative real time PCR (qPCR). Results. Initially 27 cases of tumor tissues with matched blood samples were fully analyzed by SNP microarray and qPCR. Statistical analysis using the genomic identification of significant targets in cancer (GISTIC) tool identified 10 regions of significant copy number gain and 11 regions of significant copy number loss. While overall pattern of genomic aberration was similar between germinoma and nongerminomatous germ cell tumors (NGGCTs), a few subtype-specific peak regions were identified. Analysis by SNP array and qPCR was replicated using an independent cohort of 35 cases. Conclusions. Frequent aberrations of CCND2 (12p13) and RB1 (13q14) suggest that Cyclin/CDK-RB-E2F pathway might play a critical role in the pathogenesis of intracranial GCTs. Frequent gain of PRDM14 (8q13) implies that transcriptional regulation of primordial germ cell specification might be an important factor in the development of this tumor. Pediatr Blood Cancer 2014;61:593–600. © 2013 Wiley Periodicals, Inc.

Additional Supporting Information may be found in the online version of this article at the publisher’s web-site.

Keita Terashima, MD, Alexander Yu, BS, Wing-Yuk T. Chow, PhD, Wei-chun J. Hsu, MD, Peikai Chen, PhD, Stephen Wong, PhD, Yeung Sam Hung, PhD, Tomonari Suzuki, MD, PhD, Ryo Nishikawa, MD, PhD, Masao Matsutani, MD, PhD, Hideo Nakamura, MD, PhD, Ho-Keung Ng, MD, Jeffrey C. Allen, MD, Kenneth D. Aldape, MD, Jack M. Su, MD, Adekunle M. Adesina, MD, PhD, Hon-chiu E. Leung, PhD, Tsz-Kwong Man, PhD, and Ching C. Lau, MD, PhD

DNA copy number; genomic profiling; intracranial germ cell tumor; loss of heterozygosity; SNP microarray

**Backgrounds.** Intracranial germ cell tumors (GCTs) are a group of rare and heterogeneous pediatric brain tumors, which show clinical and histological similarities to the more common GCTs such as ovarian or testicular tumors. Most intracranial GCTs occur at the pineal and suprasellar regions near the third ventricle and mainly affect male adolescents and young adults. Although the survival rate of pure germinoma is excellent (approximately 90% overall survival), optimal volume and dose of radiation and the role of chemotherapy is not clear [1–4]. In contrast, the outcome of nongerminomatous germ cell tumors (NGGCTs), a heterogeneous group including teratoma, yolk sac tumor, choriocarcinoma, and embryonal carcinoma, is poor (approximately 60% overall survival) and the standard treatment for NGGCTs remains controversial [2,5–8]. Since the treatment of intracranial GCTs is different depending on the subtype, accurate subclassification of these tumors is critically important.

The anatomic location of most intracranial GCTs makes their surgical management very challenging. Currently, stereotactic or endoscopic biopsy is the mainstay for diagnosing intracranial GCTs and some NGGCTs can be diagnosed without biopsy based on tumor markers in serum and cerebrospinal fluid (CSF): alpha fetoprotein (AFP) and/or beta human chorionic gonadotropin (BHC). However, NGGCT is quite a heterogeneous group of tumors often mixed with multiple subtypes and their clinical behavior is unpredictable. Thus novel genetic signatures which can complement conventional methods of subclassification and risk stratification are needed. While surgical resection, radiation therapy and chemotherapy can be effective, these conventional modalities also have high morbidity associated with them [3,9]. Therefore, the discovery of novel targeted therapy is essential to further improve the outcome of patients with intracranial GCTs.

Because of the scarcity of tissue samples available, very little basic research had been carried out and the biology of intracranial GCTs is poorly understood. For example, the cell of origin of intracranial GCTs is still controversial and the molecular mechanism of tumorigenesis remains elusive. Cytogenetic and molecular data of intracranial GCTs are sparse with only a handful...
of reports on the cytogenetic analysis available [10,11]. Results of comparative genomic hybridizations (CGH) and single nucleotide polymorphism (SNP) microarrays of intracranial GCTs in smaller series have been reported [12–14]. Presently, no convincing evidence implicating the involvement of particular genes or pathways in the tumorigenesis of intracranial GCTs has been identified.

To comprehensively analyze the genome-wide CNAs and loss of heterozygosity (LOH) of intracranial GCTs, we have studied a series of 62 intracranial GCTs by using high-density oligonucleotide SNP array and quantitative real time PCR (qPCR). This study was conducted as an international collaboration of six institutions to overcome the obstacle of tissue scarcity.

MATERIALS AND METHODS

Samples

Sixty-two cases from six institutions were enrolled through local Institutional Review Board-approved protocols after written informed consents were obtained. All tumor tissues and peripheral blood were collected at the time of initial surgery prior to any adjuvant treatment and were snap frozen in liquid nitrogen and stored at −80°C until the time of DNA extraction. Diagnosis was made at each local institution based on clinical, laboratory and histopathologic evaluation. Initially 27 cases with both tumor tissues and matched blood samples were analyzed by SNP array and the results were validated by qPCR method. Then SNP array data of 21 cases without matched control were analyzed independently using pooled blood controls. Likewise, qPCR study was replicated with 25 cases and 11 of which also have SNP array data from the second cohort (Table 1). Thus a total of 35 independent cases were used in the validation by either SNP array or qPCR.

DNA Extraction and SNP Microarray Hybridization

Genomic DNA was extracted from each tumor sample by QIAamp DNA Mini Kit (Qiagen, Valencia, CA) and blood sample by Wizard Genomic DNA Purification Kit (Promega, Madison, WI) according to the manufacturer’s protocols and quantified by spectrophotometry (Nanodrop, Wilmington, DE) with quality checked on 1% agarose gel. SNP array profiling was performed using Affymetrix GeneChip Human Mapping 100K Arrays (Hind III array) and a GeneChip Scanner 3000 (Affymetrix, Inc., Santa Clara, CA). Data processing was done using the Affymetrix GCOS and GDAS software according to the manufacturer’s instructions. Samples were excluded from further analysis if the call rate was less than 90%, the outlier rate was more than 5% or hierarchical tree showed distinct clustering.

Copy Number and LOH Analysis

CEL files produced by GCOS software for the qualified arrays were imported into Partek Genomic Suite (Partek, St. Louis, MO) and analyzed using the copy number analysis and LOH workflow. Signal intensity of each tumor case was compared either with paired reference blood control or pooled data of blood controls. Copy number was determined based on the signal intensity ratio between cases and controls. Significantly different regions were determined using the genomic segmentation algorithm of the Partek Genomic Suite. Each genomic region was defined as CNA when the regional copy number average was < 1.5 for loss and > 2.5 for gain. For LOH analysis, the probability of observing a heterozygous SNP in a region of LOH was determined using the genotype error rate. In a region without LOH, the probability of observing a heterozygous SNP was estimated using the observed frequency from the germline control samples. Homozygous SNPs in the control samples were excluded from the analysis. The frequency of CNA and copy neutral LOH were calculated for each segment based on the number of positive cases over total number of cases. Database of Genomic Variants (DGV) hosted by The Centre for Applied Genomics (http://projects.tcag.ca/variation/) was used to check germline copy number variation (CNV).

Quantitative Real-Time PCR (qPCR)

CCND2 and NANOQ from chromosome 12p, PRDM14 from 8q, RB1 from 13q and AR from X were selected for validation in regions of CNA. Copy number of CCND2, PRDM14, and RB1 were further validated by qPCR using the expanded cohort. Quantitative PCR by SYBR Green was performed on an ABI Prism 7900 system (Applied Biosystems, Foster City, CA). Conditions for amplification were as follows: 1 cycle at 95°C for 10 minutes, 40 cycles at 95°C for 30 seconds/62°C for 1 minute/72°C for 30 seconds, and 1 cycle at 95°C for 1 minute/60°C for 10 minutes (dissociation curve). All primer sequences are listed in Table SI. B2M and PTrace genes were selected as normal internal controls for the relative quantification. Commercially available genomic DNA (Human Genomic DNA: Promega) was used as normal external control. As a positive control for X chromosome copy number gain, blood DNA sample of individuals with karyotypes 47,XXX, 48,XXX, and 49,XXXXXY (Coriell Institute, Camden, NJ) were used.

Copy Number Determination by qPCR Method

Mean threshold cycle (Ct) values from triplicates for each sample were normalized by delta-delta C t (ΔΔC t) method, and inferred copy number (ICN) was calculated using the formula: ICN = 2 ΔΔC t. The reference ranges for normal copy number of each gene were established by analyses of ICN of patients’ blood samples. On the basis of mean ICN ± 2 SD, the reference intervals were set as, 1.48–2.55 for CCND2, 1.42–2.65 for NANOQ, 1.54–2.25 for PRDM14, 1.75–2.61 for RB1, 0.63–1.53 for AR in male patients, and 1.58–2.32 for AR in female patients. ICN of X chromosome in positive controls validated the methods (1.72: 47, XXX, 2.99: 48, XXX, 4.63: 49, XXXXY).

Genomic Identification of Significant Targets in Cancer (GISTIC) Analysis

GISTIC tool [15] which takes into account both the amplitude and frequency of CNAs was used to identify statistically significant regions of CNA among overall cohort and different subgroups of intracranial GCTs. The significance of CNA at a particular genomic location is determined by a test statistic computed using the segmentation log ratios of all samples. The threshold false discovery rate for GISTIC analysis was set at 0.05.
### TABLE I. Demographics and Clinical Characteristics of All 62 Subjects

<table>
<thead>
<tr>
<th>ID</th>
<th>Sex</th>
<th>Age (year)</th>
<th>Location</th>
<th>Pathological diagnosis</th>
<th>SNP array</th>
<th>qPCR</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Discovery cohort</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>F</td>
<td>7</td>
<td>Suprasellar</td>
<td>Germinoma</td>
<td>Tumor and matched blood</td>
<td>Performed</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>10</td>
<td>Pineal</td>
<td>Germinoma</td>
<td>Tumor and matched blood</td>
<td>Performed</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>11</td>
<td>Pineal + periventricular metastases</td>
<td>Germinoma</td>
<td>Tumor and matched blood</td>
<td>Performed</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>12</td>
<td>Left frontal lobe</td>
<td>Germinoma</td>
<td>Tumor and matched blood</td>
<td>Performed</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>15</td>
<td>Pineal + anterior horn</td>
<td>Germinoma</td>
<td>Tumor and matched blood</td>
<td>Performed</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>15</td>
<td>Suprasellar</td>
<td>Germinoma</td>
<td>Tumor and matched blood</td>
<td>Performed</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>17</td>
<td>Suprasellar</td>
<td>Germinoma</td>
<td>Tumor and matched blood</td>
<td>Performed</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>18</td>
<td>Suprasellar</td>
<td>Germinoma</td>
<td>Tumor and matched blood</td>
<td>Performed</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>22</td>
<td>Pineal</td>
<td>Germinoma</td>
<td>Tumor and matched blood</td>
<td>Performed</td>
</tr>
<tr>
<td>10</td>
<td>M</td>
<td>24</td>
<td>Cerebral</td>
<td>Germinoma</td>
<td>Tumor and matched blood</td>
<td>Performed</td>
</tr>
<tr>
<td>11</td>
<td>M</td>
<td>24</td>
<td>Pineal</td>
<td>Germinoma</td>
<td>Tumor and matched blood</td>
<td>Performed</td>
</tr>
<tr>
<td>12</td>
<td>M</td>
<td>20</td>
<td>Pineal</td>
<td>Germinoma with STGC</td>
<td>Tumor and matched blood</td>
<td>Performed</td>
</tr>
<tr>
<td>13</td>
<td>M</td>
<td>23</td>
<td>Basal ganglia</td>
<td>Germinoma with STGC</td>
<td>Tumor and matched blood</td>
<td>Performed</td>
</tr>
<tr>
<td>14</td>
<td>M</td>
<td>2</td>
<td>Cerebellum</td>
<td>Yolk sac tumor</td>
<td>Tumor and matched blood</td>
<td>Performed</td>
</tr>
<tr>
<td>15</td>
<td>M</td>
<td>12</td>
<td>Pineal</td>
<td>Yolk sac tumor</td>
<td>Tumor and matched blood</td>
<td>Performed</td>
</tr>
<tr>
<td>16</td>
<td>M</td>
<td>11</td>
<td>Pineal</td>
<td>Teratoma + yolk sac and trophoblastic elements</td>
<td>Tumor and matched blood</td>
<td>Performed</td>
</tr>
<tr>
<td>17</td>
<td>M</td>
<td>12</td>
<td>Basal ganglia</td>
<td>Germinoma + yolk sac tumor</td>
<td>Tumor and matched blood</td>
<td>Performed</td>
</tr>
<tr>
<td>18</td>
<td>M</td>
<td>24</td>
<td>Pineal</td>
<td>Yolk sac tumor + immature teratoma</td>
<td>Tumor and matched blood</td>
<td>Performed</td>
</tr>
<tr>
<td>19</td>
<td>F</td>
<td>5</td>
<td>Suprasellar</td>
<td>Immature teratoma + embryonal carcinoma + choriocarcinoma</td>
<td>Tumor and matched blood</td>
<td>Performed</td>
</tr>
<tr>
<td>20</td>
<td>M</td>
<td>14</td>
<td>Pineal</td>
<td>Germinoma + embryonal carcinoma</td>
<td>Tumor and matched blood</td>
<td>Performed</td>
</tr>
<tr>
<td>21</td>
<td>M</td>
<td>8</td>
<td>Pineal</td>
<td>Immature teratoma + germinoma</td>
<td>Tumor and matched blood</td>
<td>Performed</td>
</tr>
<tr>
<td>22</td>
<td>F</td>
<td>10</td>
<td>Suprasellar</td>
<td>Immature teratoma + germinoma</td>
<td>Tumor and matched blood</td>
<td>Performed</td>
</tr>
<tr>
<td>23</td>
<td>M</td>
<td>21</td>
<td>Pineal</td>
<td>Immature teratoma</td>
<td>Tumor and matched blood</td>
<td>Performed</td>
</tr>
<tr>
<td>24</td>
<td>M</td>
<td>4</td>
<td>Posterior fossa</td>
<td>Mature teratoma</td>
<td>Tumor and matched blood</td>
<td>Performed</td>
</tr>
<tr>
<td>25</td>
<td>M</td>
<td>10</td>
<td>Pineal</td>
<td>Germinoma + mature teratoma</td>
<td>Tumor and matched blood</td>
<td>Performed</td>
</tr>
<tr>
<td>26</td>
<td>F</td>
<td>14</td>
<td>Left frontal lobe</td>
<td>Germinoma</td>
<td>Tumor and matched blood</td>
<td>N/A</td>
</tr>
<tr>
<td>27</td>
<td>M</td>
<td>16</td>
<td>Basal ganglia</td>
<td>Germinoma</td>
<td>Tumor and matched blood</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Replication cohort</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>M</td>
<td>17</td>
<td>Pineal</td>
<td>Germinoma</td>
<td>Tumor only</td>
<td>Performed</td>
</tr>
<tr>
<td>29</td>
<td>M</td>
<td>17</td>
<td>Pineal + suprasellar</td>
<td>Germinoma</td>
<td>Tumor only</td>
<td>Performed</td>
</tr>
<tr>
<td>30</td>
<td>M</td>
<td>18</td>
<td>Pineal + anterior horn</td>
<td>Germinoma</td>
<td>Tumor only</td>
<td>Performed</td>
</tr>
<tr>
<td>31</td>
<td>F</td>
<td>24</td>
<td>Suprasellar</td>
<td>Germinoma</td>
<td>Tumor only</td>
<td>Performed</td>
</tr>
<tr>
<td>32</td>
<td>M</td>
<td>27</td>
<td>Pineal</td>
<td>Germinoma</td>
<td>Tumor only</td>
<td>Performed</td>
</tr>
<tr>
<td>33</td>
<td>M</td>
<td>14</td>
<td>Suprasellar</td>
<td>Germinoma with STGC</td>
<td>Tumor only</td>
<td>Performed</td>
</tr>
<tr>
<td>34</td>
<td>M</td>
<td>12</td>
<td>Pineal</td>
<td>Yolk sac tumor</td>
<td>Tumor only</td>
<td>Performed</td>
</tr>
<tr>
<td>35</td>
<td>M</td>
<td>13</td>
<td>Pineal</td>
<td>Immature teratoma</td>
<td>Tumor only</td>
<td>Performed</td>
</tr>
<tr>
<td>36</td>
<td>M</td>
<td>16</td>
<td>Pineal</td>
<td>Germinoma + immature teratoma</td>
<td>Tumor only</td>
<td>Performed</td>
</tr>
<tr>
<td>37</td>
<td>M</td>
<td>15</td>
<td>Pineal</td>
<td>Mature teratoma + germinoma with STGC</td>
<td>Tumor only</td>
<td>Performed</td>
</tr>
<tr>
<td>38</td>
<td>M</td>
<td>19</td>
<td>Pineal</td>
<td>Mixed germ cell tumor</td>
<td>Tumor only</td>
<td>Performed</td>
</tr>
<tr>
<td>39</td>
<td>M</td>
<td>4</td>
<td>Pineal</td>
<td>Germinoma</td>
<td>Tumor only</td>
<td>N/A</td>
</tr>
<tr>
<td>40</td>
<td>M</td>
<td>14</td>
<td>Pineal</td>
<td>Germinoma</td>
<td>Tumor only</td>
<td>N/A</td>
</tr>
<tr>
<td>41</td>
<td>F</td>
<td>18</td>
<td>Corpus callosum</td>
<td>Germinoma</td>
<td>Tumor only</td>
<td>N/A</td>
</tr>
<tr>
<td>42</td>
<td>M</td>
<td>18</td>
<td>Pineal</td>
<td>Germinoma</td>
<td>Tumor only</td>
<td>N/A</td>
</tr>
<tr>
<td>43</td>
<td>M</td>
<td>19</td>
<td>Pineal</td>
<td>Germinoma</td>
<td>Tumor only</td>
<td>N/A</td>
</tr>
<tr>
<td>44</td>
<td>F</td>
<td>25</td>
<td>Hypothalamus</td>
<td>Germinoma</td>
<td>Tumor only</td>
<td>N/A</td>
</tr>
<tr>
<td>45</td>
<td>M</td>
<td>32</td>
<td>Third ventricle</td>
<td>Germinoma</td>
<td>Tumor only</td>
<td>N/A</td>
</tr>
<tr>
<td>46</td>
<td>M</td>
<td>26</td>
<td>Pineal</td>
<td>Embryonal carcinoma</td>
<td>Tumor only</td>
<td>N/A</td>
</tr>
<tr>
<td>47</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>48</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>Tumor only</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>49</td>
<td>M</td>
<td>7</td>
<td>Basal ganglia</td>
<td>Germinoma</td>
<td>N/A</td>
<td>Performed</td>
</tr>
<tr>
<td>50</td>
<td>F</td>
<td>8</td>
<td>Suprasellar</td>
<td>Germinoma</td>
<td>N/A</td>
<td>Performed</td>
</tr>
<tr>
<td>51</td>
<td>M</td>
<td>8</td>
<td>Suprasellar</td>
<td>Germinoma</td>
<td>N/A</td>
<td>Performed</td>
</tr>
<tr>
<td>52</td>
<td>M</td>
<td>13</td>
<td>Pineal + suprasellar</td>
<td>Germinoma</td>
<td>N/A</td>
<td>Performed</td>
</tr>
<tr>
<td>53</td>
<td>M</td>
<td>16</td>
<td>Pineal</td>
<td>Germinoma</td>
<td>N/A</td>
<td>Performed</td>
</tr>
<tr>
<td>54</td>
<td>M</td>
<td>16</td>
<td>Basal ganglia + temporal lobe</td>
<td>Germinoma</td>
<td>N/A</td>
<td>Performed</td>
</tr>
<tr>
<td>55</td>
<td>M</td>
<td>25</td>
<td>Pineal + suprasellar</td>
<td>Germinoma</td>
<td>N/A</td>
<td>Performed</td>
</tr>
</tbody>
</table>

(Continued)
TABLE I. (Continued)

<table>
<thead>
<tr>
<th>ID</th>
<th>Sex</th>
<th>Age (year)</th>
<th>Location</th>
<th>Pathological diagnosis</th>
<th>SNP array</th>
<th>qPCR</th>
</tr>
</thead>
<tbody>
<tr>
<td>56</td>
<td>M</td>
<td>40</td>
<td>Pineal + basal ganglia</td>
<td>Germinoma</td>
<td>N/A</td>
<td>Performed</td>
</tr>
<tr>
<td>57</td>
<td>F</td>
<td>4</td>
<td>Suprasellar</td>
<td>Immature teratoma</td>
<td>N/A</td>
<td>Performed</td>
</tr>
<tr>
<td>58</td>
<td>M</td>
<td>10</td>
<td>Pineal</td>
<td>Immature teratoma</td>
<td>N/A</td>
<td>Performed</td>
</tr>
<tr>
<td>59</td>
<td>M</td>
<td>16</td>
<td>Pineal</td>
<td>Immature teratoma</td>
<td>N/A</td>
<td>Performed</td>
</tr>
<tr>
<td>60</td>
<td>M</td>
<td>10</td>
<td>Pineal</td>
<td>Germinoma + Teratoma</td>
<td>N/A</td>
<td>Performed</td>
</tr>
<tr>
<td>61</td>
<td>M</td>
<td>22</td>
<td>Pineal</td>
<td>Teratoma</td>
<td>N/A</td>
<td>Performed</td>
</tr>
<tr>
<td>62</td>
<td>M</td>
<td>0</td>
<td>Cerebellar</td>
<td>Mature teratoma</td>
<td>N/A</td>
<td>Performed</td>
</tr>
</tbody>
</table>

RESULTS

Copy Number and LOH Analysis by SNP Microarray

The demographic and clinical characteristics of all 62 cases are summarized in Table I. The median age of patients was 15 years (range, 8 months–40 years) and there is a male predominance (80%). Germinoma was the most common histologic subtype (63%). Tumors were most commonly located at the pineal (58%) and suprasellar (20%) regions.

After stringent quality control evaluation, 48 cases were included in the final SNP array analysis. Cases with low call rate (<90%) and high outlier rate (>5%) were excluded. These 48 cases were divided into two cohorts. Twenty seven cases of tumor tissues with matched blood samples were analyzed as a discovery set with the remaining 21 cases without matched blood DNA analyzed separately as a validation set. The tumor genomes of intracranial GCTs are often complex with multiple CNAs and LOHs in each case and virtually all cases (Fig. 1A). The size of CNAs ranged from small intrachromosomal segments to those involving entire chromosomes. Several regions of recurrent CNAs were identified. Most frequently observed copy number gains were regions on chromosomes 1q (44%), 2p (37%), 7q (37%), 8q (41%), 12p (59%), 14 (33%), 20q (30%), 21 (63%), 22 (41%), and Xq (44%). Frequently observed copy number losses were regions on chromosomes 1p (26%), 4q (26%), 5q (33%), 9q (30%), 10q (37%), 11q (41%), and 13 (48%) (Fig. 1A). Most copy number gains are of relatively low level. However, we identified 28 regions with more than five copies (mean copy number > 4.5). These regions were generally small focal segments with median size of 1.7 Mb (range: 0.1–151 Mb). They also showed a tendency to recur in some particular cases (Table II). No homoyzogous loss was identified. We identified two regions with recurrent copy neutral LOH at 11q (15%) and Xq (11%) (Fig. 1A).

GISTIC Analysis

Next, we used the GISTIC tool to identify the most significant regions of CNAs. Despite overall complex genomic aberration patterns with almost every region of the genome having CNA in at least one case, only 10 peak regions with gain and 11 peak regions with loss were identified using GISTIC analysis (Fig. 2A and Table SII). Some peaks occurred within background broad regions (e.g., gain of 8q13.2), but other peaks occurred focally without background broad regions (e.g., gain of 14q11.2). A total of 460 genes were identified at four focal peak regions: 8q13.2 gain, 14q11.2 gain, 22q11.22 gain, 1p36.12 loss (Table SIII).

SNP array data from germinomas and NGGCTs were also analyzed separately by GISTIC tool (Figs. 2B,C and Table SII). Most peak regions were detected in both subtypes, but a few subtype-specific peak regions emerged. Gain peaks at cytoband 2q22.2, 8q13, 7p15.1, 14q11.2 and a loss peak at 5p14.3 were only observed in germinomas. On the other hand, a focal loss peak at 5q32 was seen only in NGGCTs.

Subsequently, we analyzed SNP array data of 21 independent cases without matched blood as a replication cohort using pooled blood controls. Though GISTIC detected more peak regions than the analysis in the discovery cohort with matched blood controls, overall profile of DNA copy number was similar (Fig. S1). Most additional peaks detected in the analysis of the replication cohort were very narrow localized peaks, suggesting germline CNV, which cannot be distinguished from somatic aberration without matched germline control DNA. Among 45 peaks which were not detected in the first cohort with matched blood controls, 37 peaks (82%) were reported in DGV as CNVs in the normal population.

Validation of SNP Microarray Results by qPCR

In order to validate the CNAs identified by SNP array analysis in the discovery cohort of 27 cases, we performed real time qPCR. CCND2 (12p13), NANOG (12p13), PRDM14 (8q13), RB1 (13q14), and AR (Xq12) were selected for validation because of their location at the most commonly overlapped regions of frequent CNAs. Overall, there was a good concordance of the copy number calls between the SNP array and qPCR results; CCND2 (12p13): 88%, NANOG (12p13): 83%, PRDM14 (8q13): 75%, RB1 (13q14): 88%, AR (Xq12) for male: 77%, and AR (Xq12) for female: 83% (Table SIV). The copy number of CCND2, PRDM14, and RB1 in the replication cohort of 25 cases was also quantified by qPCR method. The frequency of CCND2 gain, PRDM14 gain and RB1 loss was similar to those in the discovery cohort. CCND2 gains were more common in NOGCTs. On the other hand, PRDM14 gain and RB1 losses were more common in germinomas and such a trend was similarly observed as in the discovery cohort (Table SV).

DISCUSSION

We report here the largest study of genome-wide copy number and LOH analysis of intracranial GCTs by SNP array. We detected genomic aberrations with higher sensitivity and definition than previous reports by chromosomal CGH method. In contrary to testicular GCTs, in which genomic aberration has been extensively
studied, only two small series (15 and 19 cases, respectively) of conventional CGH analysis and one series (15 cases) of SNP array CNA analysis of intracranial GCTs are available [12–14]. Our series is larger and includes 62 cases with 27 matched blood control samples. Our analysis detected most recurrent genomic aberrations which were previously reported in intracranial GCTs but with more refined boundaries. In addition, we were able to detect novel small focal regions of genomic aberration and copy neutral LOH. The DNA copy number calls by SNP array and Partek Genomic Suite were validated by qPCR method. Concordance rates of four representative loci were 75–88%. There is a trend that qPCR would call normal in a minority of cases which SNP array called abnormal. This could be due to the relatively wide normal range calculated from the data from blood samples, which could contain rare germline CNVs within the PCR amplicons.

Fig. 1. DNA copy number and LOH profile of the discovery cohort. A: genome-wide copy number and LOH profiles of 27 intracranial GCTs were analyzed by SNP microarray. Red, green, and blue indicate gain, copy-number neutral LOH, and loss of genomic regions of each chromosome, respectively. B: summary of copy number aberration profiles of 27 intracranial GCTs. The frequency of copy number gain (red) and loss (blue) of genomic regions based on SNP microarray analysis are plotted and arranged according to the chromosome order along the x-axis.
between germinoma and NGGCTs, a few subtype-specific peak assay platforms or ethnic background of the subjects in each study. The difference between various studies may be due to the difference of copy number gain found on chromosome 21. The significant similarity to our findings, but identified only one region of recurrent copy number losses such as 4q, 9q, and 13, which were also frequently observed and GISTIC analysis identified a broad peak region at 11q23.

Frequent gain of chromosome 12p has been reported previously in intracranial GCTs. The characteristic isochromosome 12p found in testicular GCTs has also been found in intracranial GCTs, but majority of 12p gains in intracranial GCTs are either whole 12p arm gain or with various other complex structural abnormalities [10]. In the current series, the most significant GISTIC region was 12p13 where multiple candidate genes, such as CCND2, KRAS, NANOG, and DPPA3 (STELLA) are located. Gain of the CCND2 gene copy was detected in 14 out of 27 cases (52%) and gain of KRAS was detected in 13 out of 27 cases (48%). KRAS is one of the most frequently mutated oncogenes in a variety of human cancers and CCND2 is involved in the inactivation of the tumor suppressing activity of RB1 by phosphorylation [21]. Concordant increase in copy number and expression of KRAS and CCND2 has been observed in testicular GCTs [22]. Recently, Lee et al. [23] showed malignant transformation of murine spermatogonial stem cells (SSC) by transfecting Ras and Ccnd2 to this small pool of self-renewing stem cells in the earliest stage in spermatogenesis. We sequenced KRAS by using remaining DNA in 21 cases and detected point mutations in two cases (data not shown). Both NANOG and DPPA3 are key genes in germ cell development, specifically in the development of PGC [24]. Expression of both proteins in GCTs has also been reported previously [25,26].

The most frequently observed copy number loss was chromosome 13 with the most significant GISTIC peak region at 13q12 which contains RB1. Copy number loss and LOH of RB1 gene was detected in 13 out of 27 cases (48%) consistent with previous reports of LOH of RB1 in testicular GCTs [27]. Frequent aberration of CCND2 and RB1 suggests that Cyclin/CDK-RB-E2F pathway might play a critical role in the pathogenesis of intracranial GCTs [28]. Copy number abnormalities of multiple key genes in this pathway such as CDK4, CDK6, and CDKN2A were also observed in our series, while we did not detect recurrent mutation of these genes in these 21 cases we investigated (data not shown). Cyclin/CDK-RB-E2F pathway has been suggested as an important pathway for initiation and development of malignant germ cells in testicular GCTs [22].

Gain of X chromosome has been observed in GCTs, including intracranial GCTs [29]. We observed frequent X chromosome gains exclusively in male patients. Schneider et al. [13] reported similar result of frequent X chromosome gain in male patients and the incidence of intracranial GCT is higher in individuals with Klinefelter syndrome (XXY) [30]. Therefore, X chromosome gain is likely to be critical in the development of intracranial GCTs [10,30].

In conclusion, we report the largest series of genome-wide CNA and LOH profiles of intracranial GCTs and describe the pattern of genomic aberration. By using GISTIC analysis, statistically significant regions of CNAs, including subtype-specific CNAs were discovered. Frequent aberration of CCND2 and RB1 suggests that Cyclin/CDK-RB-E2F pathway might play a critical role in the pathogenesis of intracranial GCTs. Frequent gain of PRDM14 imply that transcriptional regulation of PGC specification might be an important function in the biology of this tumor.

TABLE II. Genomic Regions With More Than Five DNA Copies

<table>
<thead>
<tr>
<th>ID</th>
<th>Mean copy number</th>
<th>Cytoband</th>
</tr>
</thead>
<tbody>
<tr>
<td>26</td>
<td>5.3</td>
<td>1p36.33-p36.32</td>
</tr>
<tr>
<td>26</td>
<td>4.6</td>
<td>1q12</td>
</tr>
<tr>
<td>27</td>
<td>5.1–5.7</td>
<td>1q25.3-q41</td>
</tr>
<tr>
<td>9</td>
<td>4.6</td>
<td>4q12</td>
</tr>
<tr>
<td>16</td>
<td>5.7</td>
<td>4q13.1</td>
</tr>
<tr>
<td>18</td>
<td>5.1–5.9</td>
<td>7q36.2-q36.3</td>
</tr>
<tr>
<td>7</td>
<td>4.9–16.3</td>
<td>8q11.21-q11.3</td>
</tr>
<tr>
<td>16</td>
<td>6.3</td>
<td>8q12.1</td>
</tr>
<tr>
<td>8</td>
<td>4.9</td>
<td>8q24.23</td>
</tr>
<tr>
<td>8</td>
<td>6.3</td>
<td>11p11.12q11</td>
</tr>
<tr>
<td>18</td>
<td>7.9</td>
<td>11q11</td>
</tr>
<tr>
<td>15</td>
<td>4.6–8.8</td>
<td>12p13.2-p11.1</td>
</tr>
<tr>
<td>20</td>
<td>6.2</td>
<td>12p11.22</td>
</tr>
<tr>
<td>16</td>
<td>4.6–7.5</td>
<td>12q12.33-q11</td>
</tr>
<tr>
<td>18</td>
<td>5.8</td>
<td>12q14.1-q21.1</td>
</tr>
<tr>
<td>7</td>
<td>7.2</td>
<td>1q41.11.2</td>
</tr>
<tr>
<td>1</td>
<td>5.1</td>
<td>1q13.1</td>
</tr>
<tr>
<td>16</td>
<td>4.5</td>
<td>1q13.1</td>
</tr>
<tr>
<td>27</td>
<td>5.8</td>
<td>21q21.1-21.2</td>
</tr>
<tr>
<td>8</td>
<td>4.9</td>
<td>21q21.1-21.2</td>
</tr>
<tr>
<td>20</td>
<td>4.5</td>
<td>21q21.1-q21.2</td>
</tr>
<tr>
<td>30</td>
<td>4.6–4.8</td>
<td>21q21.1-q22.3</td>
</tr>
<tr>
<td>1</td>
<td>5.0</td>
<td>21q22.3</td>
</tr>
<tr>
<td>26</td>
<td>5.0</td>
<td>21q22.3</td>
</tr>
<tr>
<td>12</td>
<td>5.3</td>
<td>22q11.21-q11.22</td>
</tr>
<tr>
<td>3</td>
<td>4.6</td>
<td>22q11.21-q11.23</td>
</tr>
<tr>
<td>26</td>
<td>5.2</td>
<td>22q13.31</td>
</tr>
<tr>
<td>15</td>
<td>4.6</td>
<td>Xp22.33-q28</td>
</tr>
<tr>
<td>27</td>
<td>4.9</td>
<td>Xq27.2-q26</td>
</tr>
</tbody>
</table>

GISTIC identified distinct focal peak regions such as 8q13.2 gain. These peak regions are small enough to have all the genes identified within these regions. The 8q13.2 region contains PRDM14 gene, a PR-domain containing transcription factor. We identified a gain peak which encompasses PRDM14 in 13 out of 27 cases (48%), eight of which were germinoma cases. PRDM14 is one of the key transcriptional regulators of primordial germ cell (PGC) specification and over-expression of PRDM14 has been reported in other cancers [16–19]. Recently a genome wide association study of some 13 with the most significant GISTIC peak region at 13q12 which contains RB1. Copy number loss and LOH of RB1 gene was detected in 13 out of 27 cases (48%) consistent with previous reports of LOH of RB1 in testicular GCTs [27]. Frequent aberration of CCND2 and RB1 suggests that Cyclin/CDK-RB-E2F pathway might play a critical role in the pathogenesis of intracranial GCTs [28]. Copy number abnormalities of multiple key genes in this pathway such as CDK4, CDK6, and CDKN2A were also observed in our series, while we did not detect recurrent mutation of these genes in those 21 cases we investigated (data not shown). Cyclin/CDK-RB-E2F pathway has been suggested as an important pathway for initiation and development of malignant germ cells in testicular GCTs [22].

Gain of X chromosome has been observed in GCTs, including intracranial GCTs [29]. We observed frequent X chromosome gains exclusively in male patients. Schneider et al. [13] reported similar result of frequent X chromosome gain in male patients and the incidence of intracranial GCT is higher in individuals with Klinefelter syndrome (XXY) [30]. Therefore, X chromosome gain is likely to be critical in the development of intracranial GCTs [10,30].

In conclusion, we report the largest series of genome-wide CNA and LOH profiles of intracranial GCTs and describe the pattern of genomic aberration. By using GISTIC analysis, statistically significant regions of CNAs, including subtype-specific CNAs were discovered. Frequent aberration of CCND2 and RB1 suggests that Cyclin/CDK-RB-E2F pathway might play a critical role in the pathogenesis of intracranial GCTs. Frequent gain of PRDM14 imply that transcriptional regulation of PGC specification might be an important function in the biology of this tumor.
REFERENCES


Fig. 2. GISTIC analysis of copy number aberration in the discovery cohort. The statistical significance of the aberrations is displayed as FDR q values to correct for multiple-hypothesis testing. Chromosome positions are indicated along the y-axis with centromere positions indicated by dotted lines. Red plot indicates gain events and blue plot indicates loss events. A: All 27 intracranial GCT cases. Ten peak regions with gain and 11 peak regions with loss are identified. B: GISTIC analysis of 15 germinoma cases. C: GISTIC analysis of 12 NGGCT cases.